Medication Review Models for Safer Community Prescribing

Abstract

Medication review models have become integral to contemporary community prescribing, aiming to enhance patient safety, optimize therapeutic outcomes, and minimize medication-related harm. This article synthesizes recent evidence on the epidemiology, risk factors, mechanisms, and clinical implications of medication review interventions, with a focus on their application in primary care settings. Emerging models, advances in digital tools, and updated guideline recommendations are discussed to provide a comprehensive resource for clinicians engaged in medication management and patient safety improvement.

Introduction

Community prescribing is a central element of ambulatory care, yet it is frequently complicated by polypharmacy, inappropriate prescribing, and medication errors. Medication review a structured, systematic evaluation of a patient’s medications seeks to address these challenges by ensuring that drug therapy remains appropriate, effective, and safe. Increasingly, regulatory bodies and professional organizations advocate for regular medication reviews as a standard of care. This review explores the scientific basis, clinical utility, and evolving models of medication review within community prescribing, highlighting recent developments and best-practice recommendations.

Epidemiology / Disease Burden

Globally, medication errors in the community setting account for a significant proportion of preventable adverse drug events (ADEs), with the World Health Organization estimating that medication-related harm ranks as a leading cause of morbidity and mortality. Older adults, who are disproportionately affected by multimorbidity and polypharmacy, are at elevated risk. In the United Kingdom, studies report that up to 11% of unplanned hospital admissions in older patients are medication-related, most of which are preventable with timely and effective medication review. The growing prevalence of chronic disease, aging populations, and increased use of high-risk medications underscore the urgent need for robust medication review systems.

Pathophysiology

The pathophysiological basis for medication-related harm in community prescribing is multifactorial. Drug interactions, inappropriate dosing, renal or hepatic impairment, and pharmacogenetic variability can all precipitate adverse outcomes. Polypharmacy increases the complexity of drug regimens, escalating the risk of pharmacodynamic and pharmacokinetic interactions. Additionally, age-related changes in metabolism and excretion further complicate medication management, necessitating individualized review. Mechanistic understanding of drug-drug and drug-disease interactions underpins the rationale for regular, comprehensive medication reviews in at-risk populations.

Risk Factors

Key risk factors for medication-related harm include advanced age, multiple comorbidities, polypharmacy (commonly defined as the concurrent use of five or more medications), cognitive impairment, renal or hepatic dysfunction, and recent hospital discharge. Social determinants, such as health literacy, fragmented care, and lack of medication reconciliation during care transitions, also contribute. Notably, certain drug classes anticoagulants, antiplatelets, antidiabetics, opioids, and psychotropics carry higher risks for ADEs and should flag the need for comprehensive review.

Clinical Features

Adverse drug events may present with a wide array of clinical features, ranging from mild symptoms such as dizziness and gastrointestinal upset to severe outcomes including falls, acute kidney injury, bleeding, hypoglycemia, and delirium. In community settings, these events are frequently under-recognized or misattributed to underlying chronic disease. A systematic medication review can help delineate drug-related symptoms from disease progression, guiding safer prescribing decisions.

Diagnosis

Diagnosing medication-related problems requires a structured and multidisciplinary approach, combining patient history, medication reconciliation, review of laboratory and monitoring data, and clinical judgement. Standardized tools, such as the STOPP/START criteria, Beers Criteria, and the Medication Appropriateness Index, facilitate the identification of potentially inappropriate medications and omission of indicated therapies. Pharmacist-led reviews, increasingly supported by digital health platforms, enhance the accuracy and efficiency of the diagnostic process.

Treatment & Management

The core of medication review involves deprescribing unnecessary or harmful medications, optimizing therapeutic regimens, and improving patient adherence. Interventions are individualized, with a focus on shared decision-making and patient education. Multidisciplinary teams including physicians, pharmacists, nurses, and, where appropriate, caregivers collaborate to reconcile medications, monitor therapeutic response, and adjust therapy as clinical status evolves. Documentation and communication among care providers are essential for continuity and safety.

Recent Advances / Emerging Therapies

Recent advances in medication review models emphasize the integration of health information technology, such as electronic prescribing systems, clinical decision support tools, and telemedicine platforms, to streamline identification of medication risks and facilitate remote reviews. Artificial intelligence and predictive analytics are being piloted to flag high-risk patients and suggest interventions proactively. Pharmacogenomic testing is emerging as an adjunct in personalizing medication regimens, particularly in populations with complex comorbidities. These innovations promise to enhance the precision and impact of medication review interventions in community settings.

Guideline Recommendations

Several professional bodies, including the National Institute for Health and Care Excellence (NICE), American Geriatrics Society, and World Health Organization, advocate for systematic medication review as a core component of patient safety strategies in primary care. Guidelines recommend at least annual reviews for older adults and those on multiple medications, with more frequent assessments in high-risk populations. Emphasis is placed on patient-centered care, interprofessional collaboration, and the use of validated assessment tools.

Conclusion

Medication review is a scientifically grounded, clinically essential practice that directly addresses the complexities and risks inherent in community prescribing. Through systematic evaluation, multidisciplinary collaboration, and the integration of technological advances, medication review models have demonstrated significant potential to improve patient safety and therapeutic outcomes. Continued research, implementation of evolving guidelines, and commitment to patient-centered care will ensure that medication review remains a cornerstone of safe, effective community prescribing.